Should all patients with immune‐mediated thrombotic thrombocytopenic purpura receive caplacizumab?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Should all patients with immune‐mediated thrombotic thrombocytopenic purpura receive caplacizumab?

Published:2020-12-17 Issue:1 Volume:19 Page:58-67
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Picod Adrien¹,Veyradier Agnès¹²³,Coppo Paul¹⁴⁵

Affiliation:

1. Centre National de Référence des MicroAngiopathies Thrombotiques Paris France

2. Service d’hématologie biologiqueHôpital LariboisièreAssistance Publique – Hôpitaux de Paris Paris France

3. EA‐3518Institut de recherche Saint LouisUniversité de Paris France

4. Service d’hématologieHôpital Saint‐AntoineAssistance publique ‐ Hôpitaux de ParisSorbonne‐Université (AP‐HP.6) Paris France

5. INSERM UMRS 1138Centre de Recherche des Cordeliers Paris France

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.15194

Reference42 articles.

1. Thrombotic thrombocytopenic purpura

2. Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features

3. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center

4. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy

5. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Caplacizumab as an add-on therapy in a 7-year-old girl with exacerbated immune-mediated thrombotic thrombocytopenic purpura, a case report and literature review;Frontiers in Pediatrics;2024-08-21

2. Iatrogenic hemorrhage and extensive venous thromboembolism during iTTP treatment with caplacizumab—A case report;eJHaem;2024-06-10

3. Efficacy and relative safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: a systematic review and meta-analysis;Blood Coagulation & Fibrinolysis;2024-06-10

4. Diagnosis and clinical management of thrombotic thrombocytopenic purpura (TTP): a consensus statement from the TTP Catalan group;BLOOD TRANSFUS-ITALY;2024

5. Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons;Expert Review of Hematology;2024-02-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3